Slide 1: Investor Presentation
INVESTOR PRESENTATION Ofer Haviv, President & CEO September 2022
Slide 2: Forward Looking Statement
Forward Looking Statement 2 This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding
Slide 3: Agenda
Agenda About Evogene Business model Product-oriented subsidiaries Summary Annex I - Financial Fundamentals 3
Slide 4: Decoding Biology: Our Vision
DECODING BIOLOGY 4 OUR VISION Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.
Slide 5: Life-science product development
Life-science product development Low probability of success with high cost and long time-to-market Pharmaceutical Industry Ag-chemicals Industry Cost of developing a single pharmaceutical drug In the 1970’s $180 million In recent years >$2 billion Years to develop a new crop protection product 1995
Slide 6: Life-science product development: finding the needle in the haystack
Life-science product development The ultimate case of finding “the needle in the haystack” Discovery Optimization Development Regulation Agriculture Product Candidates Approved Product Pharma The challenge: Finding the winning candidates out of a vast number of possible prospects that address a comp
Slide 7: Utilizing an advanced computational biology platform
Utilizing an advanced computational biology platform To identify the most promising candidates addressing multiple development challenges towards successful life-science products Increase probability of success Reduce time and cost 7 HUMAN HEALTH AGRICULTURE OTHER INDUSTRIES The opportunity
Slide 8: Biology meets disruptive technologies
Biology meets disruptive technologies BIG DATA BIOLOGY AI* platform Incorporates deep scientific understandings together with big data and advanced AI technologies, to successfully discover & guide the development of novel life-science based products. – Computational Predictive Biology *Artificial i
Slide 9: Tailor-made Tech Engines for product discovery & development
Tailor-made Tech Engines for product discovery & development The CPB platform enhances product discovery and development through dedicated Technology Engines for products based on three core components: Microbes Small molecules Genetic elements MICROBES 9 GENETIC ELEMENTS SMALL MOLECULES
Slide 10: Example of Tech Engine User Interface
Example of Tech Engine User Interface 10
Slide 11: Tailor-made Tech Engines: Discovery and Development
Discovery Computational selection of the most promising candidates to initiate the product development process. Development Computational driven solution addressing optimization development challenges for the selected candidates, without impairing their ability to address other product attributes, s
Slide 12: Building an Ecosystem around our tech engines
Plastic Degradation Chemicals Source for Enzymes Oil Spill Clearing Wastewater Treatments Microbials for Crops Food Human & Animal Probiotics Therapeutic microbials Probiotics Dietary Supplements Building an ’Ecosystem’ around our tech engines ‘Ecosystem’ – Potential Markets for MicroBoost AI 12
Slide 13: Computational Biology Peer Companies
2 Computational Biology Peer Companies Company Ticker EVGN DNA SDGR EXAI RLAY 13
Slide 14: Agenda
Agenda About Evogene Business model Product-oriented subsidiaries Summary Annex I - Financial Fundamentals 14
Slide 15: Evogene Tech Engine – Potential Addressable Markets
Plastic degradation Chemicals Source for enzymes Oil spill clearing Waste-water treatments Microbials for crops Food Human & animal probiotics Therapeutic microbials Probiotics Dietary supplements Evogene Tech Engine – Potential Addressable Markets MICROBES GENETIC ELEMENTS SMALL MOLECULES Fragrance
Slide 16: Product-oriented subsidiaries powered by Evogene's technology
Product-oriented subsidiaries powered by Evogene’s technology Establish independent entities focusing on a defined commercial field with a license to use Evogene’s unique solutions for product development Business Model Microbiome based therapeutics Medical cannabis Ag-solutions for castor Ag-chemic
Slide 17: Business Model: Collaborations
Business Model Collaborations powered by Evogene’s technology for the development of innovative products Joint development with leading companies for defined products utilizing Evogene’s unique solution. Typically, partner leads later-stage development and product commercialization. 2 Powered by Evo
Slide 18: Evogene Tech Engine – Current Utilization
Evogene Tech Engine – Current Utilization MICROBES GENETIC ELEMENTS SMALL MOLECULES Improved crops Crop protection Pharmaceuticals Medical Cannabis Microbials for crops Therapeutic microbials Castor oil Ag Seeds 18
Slide 19: Agenda
Agenda About Evogene Business model Product-oriented subsidiaries Summary Annex I - Financial Fundamentals 19
Slide 20: Product-oriented subsidiaries
20 *Evogene holdings Microbiome based Therapeutics Immuno-oncology GI- gastrointestinal- related disorders AMR - Antimicrobial resistance Ag Biologicals Bio-Stimulants Bio-Pesticides 93%* 70%* Castor Oil Production Yield improvement and drought tolerance Plant disease Insect control Ag Chemicals Her
Slide 21: Biomica: Microbiome based Therapeutics
Immuno-oncology program Combination therapy for cancer with checkpoint inhibitors Pre-clinical stage Addressable market size expected by 2026* – $243B GI related disorders Inflammatory Bowel Disorder (IBD) – pre-clinical stage Irritable Bowel Syndrome (IBS) – discovery stage Addressable market size
Slide 22: Example Results: Immuno-Oncology program BMC128
Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone Example Results: Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo | Human Microbiome Powered by 22
Slide 23: Lavie Bio: Ag-Biologicals
| Ag-Biologicals Bio-stimulants (yield enhancement) Bio-stimulants 1– focus on wheat and additional cereals. Seed treatment/soil application. Commercial stage, first sales planned in 2022. Addressable market size*: for spring wheat ±25M acres. Bio-stimulants 2 – focus on corn and additional crops. S
Slide 24: Ag-Biologicals Example Results
| Ag-Biologicals Example of treatment against Botrytis Cinerea vs untreated control in vines Lavie Bio’s wheat field in the USA during harvest – Sales initiated in 2022 Example Results: Thrivus™ inoculant LAV 311 & LAV 312 leading bio-fungicide candidates for fruit rot LAV311 & LA V312 28% 72% $10M
Slide 25: AgPlenus: Ag-Chemicals
Herbicides Novel MoA (Mode-of-Action) selective/non-selective herbicides Relevant target crops – including Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar Beet, Other TBD Addressable market size expected by 2022*: $34B Insecticides Novel SoA (Site-of-Action) – resistance breaking Addressable mar
Slide 26: Example Results: New MoA Herbicide APH1
Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1 | Ag-Chemicals Greenhouse testing of APH1 – modified tobacco plants with resistance trait vs unmodified control (weed) Example Results: New MoA Herbicide – APH1 Powered by 26
Slide 27: Canonic: Medical Cannabis Product Pipeline
MetaYield+ Products High metabolite content & consumer traits Stable enhancement of total plant compounds focused on THC, CBD and terpenes Total cannabis market size expected by 2024 – $42.7B* Precise+ Products Therapeutic traits – focus on patients’ well-being Stable enhancement of specific active
Slide 28: First Products: The G-nnovation series
First Products: The ‘G-nnovation‘ series | Medical Cannabis Powered by G200 inflorescence T20/C4 Indica Top Reported Effects Pain Relief Relaxation Improved quality sleep Muscle Relaxation G150 inflorescence T20/C4 Sativa Top Reported Effects Pain Relief Relaxation Focus Uplifting 28
Slide 29: Industry Landscape
Microbiome Based Therapeutics Ag-Biologicals Ag-Chemicals Medical Cannabis Company Market Cap/ Funds Raised Company Market Cap/ Funds Raised Company Market Cap/ Funds Raised Company Market Cap/ Funds Raised $221m* Raised $116m# (Sep 2021) Raised $70m# (July 2022) $1.1B* $124m* €216m* Raised $44m# (J
Slide 30: Agenda
Agenda About Evogene Business model Product-oriented subsidiaries Summary Annex I - Financial Fundamentals 30
Slide 31: Employees
144 Employees 28% PhDs 56% Women Microbiology 31 Biochemistry Computational chemistry Bioinformatics Incl. chairperson of the board As of September 13, 2022
Slide 32: Summary
Summary Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies. Strong computational predictive biology (CPB) platform leveraging synergies between a deep understanding of biology, Big Data and AI Business ecosystem for product d
Slide 33: Thank You
HANK YOU! evOgene —_
Slide 34: Annex I: Financial Fundamentals
Annex I: Financial Fundamentals 34
Slide 35: Key Financials: Balance Sheet
Key Financials: Balance Sheet Key Points: Consolidated cash position: ~$35 million as of 30.06.2022, of which ~$4 million is appropriated to Lavie Bio In addition, Lavie Bio received $10M in Q3 2022 from ICL No bank debt Full year net cash burn rate, excluding exchange rate impacts in 2022, is expec